PE-DeTech buys ETP
Summary
“The ETP acquisition substantially expands our product offering and realizes our market leading vision in mass spectrometry components, subassemblies and contract manufacturing,” said Jay Ray, President and CEO of DeTech.Following the merger between DeTech and SIS in January of 2018, the addition of ETP enhances the group’s manufacturing and engineering resources, allowing the aggregated group to accelerate development and prioritize value-added detection solutions for next generation client product lines.The DeTech parent company, which provides bespoke OEM R&D and production for a wide range of sample prep, automation, pumping and analytical solutions, will remain headquartered in Palmer, MA, while maintaining the recently-built world-class ETP manufacturing, development and support in Australia.With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams.Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Brammer Bio, Confluent Medical, Genewiz, Talecris Biotherapeutics and Viracor-IBT Laboratories.